FindTrial
Sign In

Alcestobart

DRUG2 trials

Sponsors

BeiGene

Conditions

HNSCC for Phase 2 Dose ExpansionLocally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-inNSCLC for Phase 2 Dose ExpansionNon Small Cell Lung Cancer

Phase 1

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
CompletedNCT03744468
BeiGeneHNSCC for Phase 2 Dose Expansion, Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, NSCLC for Phase 2 Dose Expansion
Start: 2018-11-13End: 2025-02-06Updated: 2026-04-02

Phase 2

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
CompletedNCT05577702
BeiGeneNon Small Cell Lung Cancer
Start: 2023-03-08End: 2025-01-23Updated: 2026-02-09

Related Papers

Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
Journal of Clinical Oncology2020-05-2012 citations